# Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

> clinical trial · VERIFIED · 2026-06-17

Status: RECRUITING · Sponsor: M.D. Anderson Cancer Center · Condition: T-cell Acute Lymphoblastic Leukemia

- Company: M.D. Anderson Cancer Center
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07513129

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.